A simplified method for CRISPR-Cas9 engineering of *Bacillus subtilis*

Ankita J. Sachla*[‡], Alexander J. Alfonso[‡], John D. Helmann*[‡]

[‡]Department of Microbiology, Cornell University, 370 Wing Hall, 123 Wing Drive, Ithaca, New York 14853-8101, USA

*Corresponding authors: Ankita J. Sachla and John D. Helmann, Department of Microbiology, Cornell University, 370 Wing Hall, Ithaca, New York 14853-8101, USA Telephone: 607-255-3086, Fax: 607-255-3904, Email: ajs588@cornell.edu jdh9@cornell.edu
ORCID: orcid.org/0000-0002-3850-5421 (AJS)
ORCID: orcid.org/0000-0002-3832-3249 (JDH)

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system

from *Streptococcus pyogenes* has been widely deployed as a tool for bacterial strain

construction. Conventional CRISPR-Cas9 editing strategies require design and

molecular cloning of an appropriate guide RNA (gRNA) to target genome cleavage and

a repair template for introduction of the desired site-specific genome modification. Here,

we present a streamlined method that leverages the existing collection of nearly 4000

Bacillus subtilis strains (the BKE collection) with individual genes replaced by an

integrated erythromycin (*erm*) resistance cassette. A single plasmid (pAJS23) with a

gRNA targeted to *erm* allows cleavage of the genome at any non-essential gene, and at

sites nearby to many essential genes. This plasmid can be engineered to include a

repair template, or the repair template can be co-transformed with the plasmid as either

a PCR product or genomic DNA. We demonstrate the utility of this system for

generating gene replacements, site-specific mutations, modification of intergenic

regions, and introduction of gene-reporter fusions. In sum, this strategy bypasses the

need for gRNA design and allows the facile transfer of mutations and genetic

constructions with no requirement for intermediate cloning steps.

Importance

Bacillus subtilis is a well-characterized Gram-positive model organism and a popular

platform for biotechnology. Although many different CRISPR-based genome editing

strategies have been developed for *B. subtilis*, they generally involve the design and

cloning of a specific gRNA and repair template for each application. By targeting the

erm resistance cassette with an anti-*erm* gRNA, genome-editing can be directed to any

of nearly 4000 gene disruptants within the existing BKE collection of strains. Repair

templates can be engineered as PCR products, or specific alleles and constructions can

be transformed as chromosomal DNA, thereby bypassing the need for plasmid

construction. The described method is rapid, free of off-target effects, and facilitates a

wide-range of genome manipulations.

"Healing is a matter of time, but it is sometimes also a matter of opportunity." –

Hippocrates

Introduction

Bacillus subtilis is a Gram-positive model bacterium and serves as an important

platform for industry, including the production of commodity chemicals, metabolites, and

proteins (1-3). A wide variety of approaches are available for genome modification and

editing, which are further aided by the natural competence of many laboratory strains.

One of the earliest methods for introducing directed mutations was

transformation with plasmids that lack an active origin in *B. subtilis*. Selection for a

plasmid-borne antibiotic resistance gene results in recovery of plasmid integrants, which

allows for gene disruptions or the generation of reporter fusions. This approach, as

implemented in the pMUTIN series of plasmids (4), was widely employed in early

functional genomics studies of *B. subtilis*. However, plasmids integrated by single-

crossover can have polar effects, and the integrational event is reversible when

selection is removed, leading to genetic instability.

Further refinements were soon introduced to allow introduction of mutations

stable in the absence of ongoing selection. For example, with long-flanking homology

PCR (LFH-PCR), double-crossover integration occurs at regions upstream (UP) and

downstream (DO) of the desired site of genome modification (5). This can be used to

introduce null or altered function mutations, epitope- or fluorescent protein tags, or

reporter fusions at a specific locus as long as the desired strain can be isolated by

selection or identified by screening. If there is no selection, as is often the case, an

antibiotic resistance marker can be included in the region between the UP and DO

regions of homology for selection. Mutations introduced in this manner are generally

stable in the absence of ongoing selection, but engineering strains with multiple

mutations can be limited by the available resistance cassettes. This technique was

therefore further refined using Cre/Lox-based recombination to remove the antibiotic

resistance cassette (6), and by using MazF as a counter-selectable marker (7, 8).

The development of the BKE/BKK collection of strains has greatly simplified the

generation of *B. subtilis* strains carrying null mutations (9). These collections, with

nearly 4000 strains each, contain erythromycin-resistant (BKE) or kanamycin-resistant

(BKK) single-gene replacements, and are available from the Bacillus Genetic Stock

Center (BGSC, USA) and the National BioResource Project (NBRP, Japan). Typically,

null mutations are introduced into the genetic background of choice by transformation of

genomic DNA from the chosen BKE or BKK strain with selection for the antibiotic

cassette. In a subsequent step, the strain can be by transformed with pDR244, a

temperature-sensitive plasmid expressing the Cre recombinase to excise the antibiotic

cassette leaving behind an in-frame gene deletion with a 150 bp (50 amino acid) bar-

coded scar (9). This process can be repeated to generate strains containing multiple

null mutations.

The CRISPR-Cas9 system, originally from *Streptococcus pyogenes*, has been

widely adapted for bacterial genome editing including several variants for *B. subtilis* (10-

13). CRISPR-Cas9 genome editing facilitates genetic manipulations, including the

introduction of point mutations, large deletions, epitope- or fluorescent protein tags,

regulatory site mutations, and expression of non-native genes. In addition, targeting of

inactive nucleases to specific promoter regions allows for interference with gene

expression (CRISPRi) and thereby gene repression (10, 14, 15). As often applied, the

Cas9 endonuclease is targeted to a specific site by an ~20 nt guide RNA (gRNA), and

homologous recombination with a cloned repair template allows for chromosome repair

and cell survival. The gRNA and repair template can be introduced together on a single-

plasmid system as implemented in plasmid pJOE8999 (11). While this plasmid provides

a powerful tool for a wide-variety of genome manipulations, each construct requires

design and cloning of both an appropriate gRNA and the desired repair template

containing the intended mutation together with sufficient flanking DNA for homologous

recombination. These multiple cloning steps present a bottleneck for the rapid

deployment of CRISPR-Cas9 genome engineering. This has motivated efforts to

increase the rapidity with which genomes can be edited by using strains with Cas9

expressed from an inducible chromosomal locus (10), plasmids optimized for rapid

fragment exchange (16), and introduction of repair templates by co-transformation with

PCR products (10).

Here, we have sought to streamline genome editing by leveraging the extant

BKE collection of nearly 4000 *B. subtilis* strains with individual genes replaced by an

integrated erythromycin (*erm*) resistance cassette (9). We have designed a plasmid

(pAJS23) containing a gRNA targeted to the erythromycin (*erm*) cassette. pAJS23 can

be modified to incorporate repair template DNA, or the repair template can be provided

by co-transformation with either a PCR product or chromosomal DNA. This approach

allows one-step genome editing with no need for gRNA design or plasmid cloning steps.

This single plasmid system will allow for greater accessibility and efficiency in genome

editing of *B. subtilis*.

Results

Plasmid pAJS23 encodes an *erm*-directed gRNA. Plasmid pJOE8999 has been

widely used for CRISPR-Cas9 mediated engineering in *B. subtilis* (11). Rather than

designing a unique gRNA for each application, we sought to leverage the large BKE

collection of single-gene *erm* replacements by design of an anti-*erm* gRNA. The

designed gRNA is specific to the *erm* gene, and the closest homology in the *B. subtilis*

168 genome has 4 mismatches, which thereby prevents off-target effects. The resultant

plasmid, pAJS23, allows selective cleavage of the chromosome at any site with an

integrated *erm* gene (Fig. 1). Subsequent to chromosome cleavage, homologous

recombination with a cognate repair template restores chromosome integrity to allow

survival. Here, we present several examples of genome-editing using DNA repair

templates either cloned into pAJS23, or co-transformed as either a PCR product or

genomic DNA.

Genome-editing using pAJS23 with a cloned guide RNA. As shown in previous

studies, repair DNA templates for CRISPR-Cas based *B. subtilis* genome-editing can be

provided by cloning into a plasmid (11), but can also be provided by transformation of

PCR products into cells, albeit with reduced efficiency (10). We first explored the utility

of pAJS23 for genome editing by cloning appropriate repair templates into pAJS23. For

each application, the repair template is generated containing the desired cargo (gene of

interest with or without modifications) flanked by UP and DO regions of homology for

integration into the chromosome. For cloning of the repair template into pAJS23 the

outermost primers used for UP and DO region amplification contain SfiI recognition sites

corresponding to the two SfiI sites in the parent plasmid pJOE8999 (11). Note that SfiI

recognizes the sequence GGCCNNNN/NGGCC and leaves a 3 nt 3'-overhang. The two

SfiI sites in pJOE8999 leave different overhangs (5'ACG3' and 5'TAT3'), and the

primers used to amplify the repair template should include SfiI sites that generate 3'-

overhangs (5'CGT3' and 5'ATA3') that are compatible with the vector overhangs.

For genome engineering, it is recommended to first transform the relevant gene

disruptant from the BKE collection into the desired parent strain prior to genome-editing.

This helps to ensure that all strains are isogenic except for the modified region. Next,

the pAJS23 derivative carrying the desired repair template is transformed into the strain

containing an *erm* cassette in the region between the UP and DO regions of homology.

Cleavage of the chromosome within the *erm* cassette is a potentially lethal event, and

surviving cells are enriched for those where chromosome integrity is restored by

recombination at the UP and DO homologous regions.

Gene replacement at locus. As a first application, we sought to replace an

endogenous *B. subtilis* gene with an ortholog from another organism. We targeted

cpgA, the third gene in the *prpC-prkC-cpgA-rpe-yloS* operon. The *cpgA* gene encodes a

ribosome assembly GTPase (required for growth at lower temperature) that additionally

functions as a metabolite proofreading phosphatase important under glycolytic

conditions (17). We sought to determine whether these functions are conserved among

related organisms using gene replacement to substitute, at locus, the *cpgA* coding

sequence with that of the *Staphylococcus aureus* ortholog *rsgA*.

For this application, we first generated LFH-PCR products containing three DNA

fragments corresponding to (i) an upstream region of homology from *prkC* (UP), (ii) the

Staphylococcus aureus rsgA gene (*cpgA* ortholog), and (iii) a downstream region of

homology from *rpe* (DO). The resulting 2.4 kb LFH-PCR fragment was cloned into

pAJS23 between the adjacent SfiI restriction sites to generate pAJS24, which was

transformed into BKE15780 (*cpgA*::*erm trpC2*). Transformants were selected on LB

plates at 30 ˚C with kanamycin (to select for the temperature-sensitive plasmid) and

mannose (to induce gRNA expression) for 48 h. The resultant Kan^R clones contain the

plasmid and express the anti-*erm* gRNA, so there is a strong selection for

recombinational repair. We then patched the transformants onto LB plates without

antibiotics at 42 ˚C to facilitate plasmid curing. After three passages at 42 ˚C, the

majority (89%) of the test clones were MLS sensitive (MLS^S), indicative of loss of the

erm resistance cassette (Table 1). In each case tested (10/10), the resultant *erm*

sensitive colony contained the desired gene replacement, with *cpgA* replaced by the *S.*

aureus rsgA gene (Table 1). These *cpgA::rsgA-Sau* transformants were capable of

rescuing growth defects of *cpgA* null mutants as visualized through serial dilution at

permissive (37 ˚C) and non-permissive (30 ˚C) temperature for ribosome assembly

defects (Fig 2A).

Introduction of an epitoge-tag. As a second application, we sought to incorporate a

FLAG epitope tag by modification of the *B. subtilis sodA* gene encoding superoxide

dismutase. Since *sodA* deletion strains are defective in competence (18), we chose to

use the adjacent *yqgC*::*erm* BKE strain as recipient. We generated plasmid pAJS25 to

include a 3.9 kb repair template containing the desired *sodA*-FLAG gene flanked by

upstream (*yqgB-yqgC*) and downstream (*yqgE*) genes (Fig. 2B). In this case,

recombinational repair could occur downstream of *sodA*, leading to successful

integration of the *sodA*-FLAG gene, or within the *sodA* gene. After curing of the plasmid,

most of the recovered clones (66%, Table 1) were MLS^S, consistent with loss of the *erm*

cassette. All 10 of the MLS^S transformants characterized encoded the *sodA*-FLAG

protein, which was monitored as a function of cell growth by immunoblotting with anti-

FLAG rabbit primary antibody and HRP conjugated-anti rabbit mouse secondary

antibodies (Fig. 2B).

Generation of a GFP-translational fusion. As a third application, we modified the

yqgC gene to encode a translational green fluorescent protein (GFP) fusion protein.

Plasmid pAJS26 was engineered to contain a 4.3 kb repair template encoding *yqgC-gfp*

together with flanking upstream and downstream DNA. The *yqgC::erm* strain was the

recipient for genome editing. We again recovered MLS^S colonies, and all those tested

had the desired gene fusion as verified by DNA sequencing (Table 1). The resulting

strain expressed GFP, as visualized during late stationary growth with fluorescence

microscopy (Fig 2C).

Single nucleotide changes. For a fourth application, we introduced *yceF** (an allele of

yceF with an Ile206Thr substitution) on a 2.17 kb repair template cloned into pAJS23 to

generate pAJS27. The *yceF* gene encodes a membrane protein from the TerC family

and is part of the *yceCDEFGH* operon (19). We were again able to recover the desired

recombinant strain with high yield (Table 1, Fig 2D).

Deletion of an intergenic region. As a fifth example, we deleted the intergenic region

within the *yqgC-sodA* operon, which codes for an uncharacterized RNA feature (S936)

and includes promoters for transcription of *sodA.* For this construction, the pAJS23

plasmid was modified to include a 2.2 kb repair template resulting in plasmid pAJS28.

With *yqgC*::*erm* as the recipient strain, we recovered the desired genetic construct with

high efficiency (Table 1), as confirmed by checking the size of PCR fragments spanning

the desired deletion and by DNA sequencing (Fig 2E).

Generation of clean deletions. As a final application, we introduced a Δ*yqgC* deletion

derived from the corresponding BKE strain to generate two cloned repair templates

differing in the extent of homology to the chromosome. Plasmid pAJS29 had a

combined 596 bp of homology for recombination (746 total length including 150 bp scar

region), whereas pAJS30 had 1594 bp (1744 bp total length). Both constructs were

successful, although pAJS30 gave a higher efficiency (Table 1). In general, for each of

these applications we had no difficulty in identifying MLS[S] clones after plasmid curing,

although the frequency of recovery was reduced when the length of the regions of

homology for recombination upstream or downstream of the *erm* cassette fell below 300

bp (e.g. pAJS29).

Provision of a repair template by co-transformation. Since *B. subtilis* is naturally

competent, it is possible to introduce DNA repair templates as a PCR product, as shown

previously (10). Therefore, we decided to explore genetic constructions made by co-

transforming pAJS23 with a repair template provided as either a PCR product or

genomic DNA. Since competent cells can take up multiple DNA molecules, those that

acquire both the plasmid and the repair template should be enriched among those

colonies that pass through the standard selection procedure.

To test this procedure, we used the BKE *yceF::erm* strain as recipient and

introduced *yceF** (Ile206Thr substitution) on a repair template provided either in cis (by

cloning into pAJS23), as a PCR product, or as genomic DNA (Fig 2D). When the repair

template was provided as a PCR product spanning the *yceF** gene, the efficiency of the

procedure decreased to ~18% (5/28 MLS^S clones were confirmed by sequencing). We

were also able to obtain the desired strain with a repair template provided using

genomic DNA. In two separate trials using genomic DNA we observed similar

efficiencies (11% and 13%, Table 1). With this strategy, genome editing can be done

quickly since there are no required cloning steps, and in many applications the repair

template can be provided as genomic DNA. Even though the efficiency in these

examples was not as high as with a cloned repair template, it was still straightforward to

identify clones with the desired genetic change.

Discussion

CRISPR-Cas9 and related genome-editing systems have revolutionized biology

by enabling the precise editing of complex genomes (20, 21). The applications of

CRISPR-based tools to bacterial genetics are legion and include the introduction of

changes ranging from single-nucleotide mutations (11), to large-scale chromosomal

deletions (22), the precisely tuned modulation of gene expression using CRISPR-

interference based approaches (14, 23), and the targeted integration of large regions of

up to 10 kb of DNA using Tn7-like integrases (24-26). Because of its importance in

molecular biology and numerous anticipated applications in medicine, CRISPR-based

laboratories are now included in many undergraduate curricula (27).

Here we describe an efficient method for engineering the *B. subtilis* 168 genome

that bypasses many of the steps that can be rate-limiting during genome engineering. It

is relatively easy to move selectable markers from one strain of *B. subtilis* to another by

taking advantage of natural competence. As a result, null mutations can be introduced

into any desired competent strain using genomic DNA from strains from the BKE

collection (9). This collection of nearly 4000 *erm* gene disruptants is commercially

available and individual strains can be ordered from the *Bacillus* genetic stock center

(BGSC). With a desired recipient strain in hand, genome editing can be done by either

cloning the desired repair template into pAJS23 or by providing the repair template as a

PCR product or genomic DNA from a donor strain. The efficiency of recovery of the

desired mutation is generally highest when the repair template is provided on the

plasmid. However, the reduced efficiency when using a PCR product or genomic DNA

as a repair template may be preferable when compared to the additional steps required

to clone and verify a plasmid construct for each editing application.

Genomic DNA is taken up very efficiently by competent *B. subtilis*

cells. Mutations that confer a selectable phenotype are routinely introduced by

transformation. However, moving mutations and genetic constructions that do not confer

a selectable phenotype can be more laborious, often involving screening of colonies for

co-transformation of the desired change together with a selectable marker (genetic

congression; (28, 29)). Here, we demonstrate that CRISPR-Cas9 mediated genome

cleavage can also provide a strong selection for the transfer of mutations or genetic

constructions into a recipient strain, even when it does not confer an immediately

selectable phenotype.

One application of this procedure is for studies involving the genetic basis of

phenotypes arising during experimental evolution, or in laboratory selections and

screens for particular phenotypes. The advent of cost-effective whole-genome

resequencing (WGS) has made it practical to follow evolutionary changes in great detail

as bacteria adapt to different environments. We often use WGS to identify mutations of

interest by comparison of an evolved strain to the parent strain. Depending on the

nature of the experiment, there may be only one or a few changes detected, or the

number may be much larger. It can be challenging to know which of the observed

genetic changes is causal for the observed phenotype, and it is always possible that an

undetected change is responsible. To be rigorous, it is desirable to reconstruct the

evolved strain by introduction of the presumptive causal mutation(s) into the parent

strain. This type of genetic backcrossing is important, but often non-trivial. Backcrossing

of mutations, together with genetic complementation studies, generates assurance that

the observed phenotype is correctly linked to a specific genetic change. In previous

studies, we have used CRISPR-Cas genome editing with custom gRNAs and repair

templates to reconstruct mutations (29-32). For each application, this entailed the

design and cloning of an appropriate gRNA, followed by the design and cloning of a

repair template. This experience has motivated our current efforts to develop a

streamlined procedure that will, in many cases, allow a bypass of all molecular cloning

steps and allow strain construction using genetic transformation.

B. subtilis is a convenient and safe organism for teaching laboratories. This

system is appropriate for use as a simple laboratory exercise where students can

modify a genome using CRISPR-Cas9. In addition, many undergraduate laboratories

may employ *B. subtilis* for use in authentic research experiences, such as genetic

selection or screening of mutants with interesting properties. The underlying genotypic

changes can then be identified using WGS-based approaches for a modest cost.

CRISPR-Cas9 genome editing provides an effective way to move mutations between

strains and thereby test the role of individual mutations in the phenotype of evolved

strains.

While the strategy presented here is specific for *B. subtilis* and for the BKE

collection of strains, it is straightforward to extend the idea of using a common gRNA to

other collections of bacterial strains with indexed gene disruptions (including the related

B. subtilis BKK collection). Such collections are available in many model organisms and

it is possible in other systems to introduce repair templates as PCR products using

electroporation or chemical transformation, as shown for example in *E. coli* (33).

Materials and Methods

Strains, Media, and Growth conditions.

All the strains used in this study are listed in Table S1 and all the oligos used in gene

amplification, genetic manipulations, and construct verifications are listed in Table S2.

All of the *Bacillus* erythromycin knockout (BKE) strains in 168 background were

obtained from BGSC or from the National BioResource Project (NBRP, Japan).

Experiments for *E. coli* and *B. subtilis* growth were performed in LB medium (lysogeny

broth; 5 ml in 25 ml tube) or agar (20 ml in petri plate) with appropriate antibiotics. We

used kanamycin in final concentrations of 30 μg ml^{-1} for *E. coli* and 15 μg ml^{-1} for *B.*

subtilis. The *erm* gene encodes macrolide lincosamide streptogramin (MLS) resistance

and is selected with erythromycin (1 μg ml^{-1}) and lincomycin (25 μg ml $^{-1}$). 96 well plates

with 0.1 ml of LB were inoculated with mid-log (OD 600 nm = 0.4) cultures at 50-fold

dilutions in final volume for growth measurements. These aerobic cultures were

monitored periodically every 60 min for 37 ℃ growth at 600 nm in Synergy H1 plate

reader (BioTek Instruments Inc, VT).

Erythromycin specific-guide RNA (*erm*-gRNA) cloning. To target the MLS (*erm*)

cassette we selected the 20 nt sequence 5'TTTGAAATCGGCTCAGGAAA3' followed by

AGG of PAM sequence (supplemental file S2), which spans the 35th-41st codon of *erm*.

We added BsaI compatible ends to this sequence and its reverse complement

sequence (Table S1) and oligos were mixed in 1:1 ratio (10 μM each) in TE buffer (pH

7.0). This mixture was heated at 95 °C for 10 min. and cooled to room temperature to

generate double stranded *erm*-gRNA with BsaI compatible 5' and 3' ends (Fig 1), prior

to cloning into pJOE8999 (11) digested with BsaI. The ligation reaction was transformed

into *E. coli* DH5α and plated on LB agar with X-gal (40 μg ml^{-1}) plus kanamycin. White

clones (pJOE8999 containing *erm*-gRNA) were selected and subjected to PCR

verification and sequencing at Cornell Biotechnology Resource Center facility to verify

the *erm*-gRNA insertion. Culture of *E. coli* harboring *erm*-gRNA in pJOE8999 plasmid

(pAJS23) was stored as HEAS25630 (Table S1).

Genome editing in *Bacillus* with a cloned repair template. Repair templates were

generated using overlap extension (SOEing) PCR or PCR amplification of a suitable

region from genomic DNA. The outermost primers were designed to include SfiI

restriction sites (see SI Fig 2). The PCR product was digested with SfiI and then ligated

into pAJS23 plasmid that had also been digested with SfiI and column purified to

remove the small (12 bp) excised fragment. The repair template and vector were

incubated with T4 DNA ligase enzyme at room temperature for 1 hr (or 18 hr at 16 °C),

and then transformed into *E. coli* DH5α with selection for Amp^R. The desired clone was

confirmed with analytical PCR, and then transformed into *E. coli* TG1 to generate

multimeric plasmid DNA. The resulting pAJS23 derivative can then be used for genome-

editing of the appropriate strain containing an integrated *erm* cassette.

For each application, we transformed the appropriate recipient strain from the

BKE collection with the corresponding pAJS23 derivative. Recipient cells (5 ml) were

grown in competence medium to OD 600 nm ~0.8, 1 ml was removed as a negative

control, and 1 μg plasmid was added to the remaining and culture and incubated for 2

hrs at 30 °C with shaking (250 rpm). Cells (from 1 ml culture) were plated on LB agar

containing 15 μg ml^{-1} kanamycin (to select for plasmid) and 0.2% mannose (to induce

gRNA expression) and incubated for 24-48 hrs at 30 °C. The resulting colonies were

passaged three times on LB plates (without any antibiotics) at 45 °C for 18-24 hrs each

time. The resulting clones were then tested for loss of the plasmid by patching on LB

plates with MLS, kanamycin, or no antibiotics. Alternatively, colonies may be first

patched onto LB plates at 50 °C, and then colony purified at 42 °C as previously

described (11). Clones that failed to grow when patched onto both MLS and kanamycin

test plates were selected. The presence of the desired genome change was confirmed

using PCR amplification and Sanger sequencing.

pAJS24 (*rsgA*). We amplified three overlapping fragments by PCR including *Bacillus*

prkC-fragment (767bp), the *rsgA* gene (*cpgA* ortholog) from *S. aureus* Newman

(876bp), and *rpe* (799bp). These PCR fragments were fused to generate a single PCR

fragment consisting with SfiI restriction sites for cloning into pAJS23.

pAJS25 (*sodA*-FLAG). For this FLAG epitope fusion, we chose LFH PCR based in-

frame *sodA* ORF fusion to nucleotides GATTATAAAGATGATGATGATAAA coding for

an extended DYKDDDDK fusion tag on Mn-SOD protein.

pAJS26 (YqgC-GFP). For *yqgC* gene fusion to *gfp*, we generated chimeric PCR by

individually amplifying three overlapping fragments. The fragment one consisting of

yqgB-yqgC (1205bp) and second fragment consisting of mostly 712 bp long *yqgC*

adaptors-*gfp* (taken form pGFP-star plasmid (34)-*sodA* adaptors and *sodA-yqgE*

fragment (1467bp).

pAJS27 (*yceF**). To introduce a point mutation in *yceF*, we employed LFH primers

encoding an Ile206Thr in *yceF* (*yceF**). In this approach we generated and joined two

fragments into a single fragment.

pAJS28 (ΔS936)**.** To delete the S936 RNA feature in the non-coding region between

yqgC-sodA element, we engineered a 177 bp deletion spanning reference positions

from 2586043 to 2586220 in the *Bacillus* genome NC_000964.3. We ordered a gBlock

with SfiI recognition sequences at both ends from IDT (Integrated DNA Technologies,

Inc. IA, USA), which was cloned into pAJS23 to generate pAJS25.

pAJS29 and pAJS30 (Δ*yqgC*). To convert *yqgC*::*erm* to Δ*yqgC* we selected primers

such that the length of the repair template was either 546 bp or 1594 bp (Table 1).

These repair template were PCR amplified from Δ*yqgC* genomic DNA (generated from

yqgC::*erm* using pDR244 as described; (9)). The resultant strain has an unmarked

yqgC deletion (Δ*yqgC*) with a 150 bp scar in place of the *erm* resistance cassette.

Genome editing by co-transformation with a repair template. 6 ml of recipient

Bacillus subtilis strain was transformed as above with 1 μg of pAJS23 plasmid DNA

mixed with either 1 to 2 μg of PCR DNA or with 1 μg of sheared/sonicated (20 sec. 40%

amplitude) genomic DNA. 1 ml of culture was removed as a negative control. The

competent cells were incubated with DNA at 30 °C overnight and then split into 5 x 1ml

aliquots. Cells were centrifuged for 3 min at 5000 rpm, resuspended in sterile PBS/LB

(0.1 ml), and plated onto LB containing kanamycin and 0.2 % mannose for 36-48 hrs at

30 °C. Plasmids were cured at 42 °C and the recovered clones confirmed by Sanger

sequencing as described above.

Spot dilution assay. Assay was performed as described in (17). Briefly, cultures were

streaked onto LB agar plate and incubated at 37 °C for growth. These cultures were

then grown in liquid LB broth (5 ml) till OD at 600 nm was 0.4. Then serial dilution was

performed for cells in 96 well microtiter plates. 10 μl of serially diluted cells were spotted

onto LB agar and allowed to aseptically air dry. These plates were then incubated at

either 37 or 30 °C. Plates were imaged after 18 hours.

Western blot. The *sodA*-FLAG tagged HBYL1249 cells were grown in LB at 37 °C and

0.5ml of cell culture was harvested at 0.4, 0.6, 0.8 and 1.0 OD 600nm by centrifugation

at 13,000 rpm for 5 min. Cell pellets were suspended with 50 μl of PBS and 1.0 μg of

lysozyme and incubated at 37 °C for 20 min. This culture lysate was centrifuged at

13,000 rpm for 1 min and soluble fraction was collected, protein concentration was

determined by Bradford reagent (BioRad) and separated by SDS-PAGE. Proteins were

transferred to PVDF membrane using a Trans-Blot Turbo transfer system (BioRad). The

membrane was blocked (for 1 hr) and incubated for 1 hr with primary rabbit anti-FLAG

antibody (Sigma-Aldrich). Following buffer wash the membrane was incubated for 1 hr

with HRP-conjugated IgG mouse anti-rabbit antibodies (ThermoFisher Sci.). The blot

was stained with 1:1 enhancer:substrate reagents (BioRad) for 5 min, visualized with

ChemiDoc MP imaging system (BioRad) and ImageLab software.

Epifluorescence microscopy. Candidate overnight grown cells were collected from

the plate and mixed in LB to get 0.1 OD. These cells were spotted onto agarose pad

and gently covered with a cover-slip and observed using Olympus BX61

epifluorescence (for GFP) microscope and images were captured.

ACKNOWLEDGEMENT

We thank National Institutes of Health for grant R35GM122461 awarded to JDH. We

are grateful to Josef Altenbuchner for creating pJOE8999, a pioneering plasmid for

Bacillus genome editing.

Competing Interest.

Authors declare there is no competing interest.

Author contribution

A.J.S performed all the experiments, J.D.H and A.J.S conceptualized and designed

experiments, A.J.S and A.A drafted the manuscript. J.D.H supervised, edited, and

finalized the manuscript.

453
454   Bibliography and References Cited
455
1.   van Dijl JM, Hecker M. 2013. *Bacillus subtilis*: from soil bacterium to super-secreting cell
      factory. Microb Cell Fact 12:3.
2.   Zhang X, Al-Dossary A, Hussain M, Setlow P, Li J. 2020. Applications of *Bacillus subtilis*
      Spores in Biotechnology and Advanced Materials. Appl Environ Microbiol 86.
3.   Zhang K, Su L, Wu J. 2020. Recent Advances in Recombinant Protein Production by
      Bacillus subtilis. Annual Review of Food Science and Technology 11:295-318.
4.   Vagner V, Dervyn E, Ehrlich SD. 1998. A vector for systematic gene inactivation in
      Bacillus subtilis. Microbiology (Reading) 144 (Pt 11):3097-3104.
5.   Wach A. 1996. PCR-synthesis of marker cassettes with long flanking homology regions
      for gene disruptions in *S. cerevisiae*. Yeast 12:259-65.
6.   Yan X, Yu HJ, Hong Q, Li SP. 2008. Cre/lox system and PCR-based genome engineering in
      Bacillus subtilis. Appl Environ Microbiol 74:5556-62.
7.   Yu H, Yan X, Shen W, Shen Y, Zhang J, Li S. 2010. Efficient and precise construction of
      markerless manipulations in the *Bacillus subtilis* genome. J Microbiol Biotechnol 20:45-
      53.
8.   Morimoto T, Ara K, Ozaki K, Ogasawara N. 2009. A new simple method to introduce
      marker-free deletions in the *Bacillus subtilis* genome. Genes Genet Syst 84:315-8.
9.   Koo BM, Kritikos G, Farelli JD, Todor H, Tong K, Kimsey H, Wapinski I, Galardini M, Cabal
      A, Peters JM, Hachmann AB, Rudner DZ, Allen KN, Typas A, Gross CA. 2017. Construction
      and Analysis of Two Genome-Scale Deletion Libraries for *Bacillus subtilis*. Cell Syst 4:291-
      305 e7.
10.   Westbrook AW, Moo-Young M, Chou CP. 2016. Development of a CRISPR-Cas9 Tool Kit
      for Comprehensive Engineering of *Bacillus subtilis*. Appl Environ Microbiol 82:4876-95.

479   11.   Altenbuchner J. 2016. Editing of the Bacillus subtilis Genome by the CRISPR-Cas9
480   System. Appl Environ Microbiol 82:5421-7.

481   12.   Burby PE, Simmons LA. 2017. CRISPR/Cas9 Editing of the *Bacillus subtilis* Genome. Bio
482   Protoc 7.

483   13.   Hong KQ, Liu DY, Chen T, Wang ZW. 2018. Recent advances in CRISPR/Cas9 mediated
484   genome editing in *Bacillus subtilis*. World J Microbiol Biotechnol 34:153.

485   14.   Peters JM, Colavin A, Shi H, Czarny TL, Larson MH, Wong S, Hawkins JS, Lu CHS, Koo BM,
486   Marta E, Shiver AL, Whitehead EH, Weissman JS, Brown ED, Qi LS, Huang KC, Gross CA.
487   2016. A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in
488   Bacteria. Cell 165:1493-1506.

489   15.   Hawkins JS, Silvis MR, Koo BM, Peters JM, Osadnik H, Jost M, Hearne CC, Weissman JS,
490   Todor H, Gross CA. 2020. Mismatch-CRISPRi Reveals the Co-varying Expression-Fitness
491   Relationships of Essential Genes in *Escherichia coli* and *Bacillus subtilis*. Cell Syst 11:523-
492   535 e9.

493   16.   Garcia-Moyano A, Larsen O, Gaykawad S, Christakou E, Boccadoro C, Puntervoll P,
494   Bjerga GEK. 2020. Fragment Exchange Plasmid Tools for CRISPR/Cas9-Mediated Gene
495   Integration and Protease Production in *Bacillus subtilis*. Appl Environ Microbiol 87.

496   17.   Sachla AJ, Helmann JD. 2019. A bacterial checkpoint protein for ribosome assembly
497   moonlights as an essential metabolite-proofreading enzyme. Nat Commun 10:1526.

498   18.   Ohsawa T, Tsukahara K, Sato T, Ogura M. 2006. Superoxide stress decreases expression
499   of *srfA* through inhibition of transcription of the *comQXP* quorum-sensing locus in
500   *Bacillus subtilis*. J Biochem 139:203-11.

501   19.   Paruthiyil S, Pinochet-Barros A, Huang X, Helmann JD. 2020. *Bacillus subtilis* TerC Family
502   Proteins Help Prevent Manganese Intoxication. J Bacteriol 202.

503   20.   Doudna JA, Charpentier E. 2014. Genome editing. The new frontier of genome
504   engineering with CRISPR-Cas9. Science 346:1258096.

505   21.   Shalem O, Sanjana NE, Zhang F. 2015. High-throughput functional genomics using
506   CRISPR–Cas9. Nature Reviews Genetics 16:299-311.

507   22.   So Y, Park SY, Park EH, Park SH, Kim EJ, Pan JG, Choi SK. 2017. A Highly Efficient CRISPR-
508   Cas9-Mediated Large Genomic Deletion in *Bacillus subtilis*. Front Microbiol 8:1167.

509   23.   Price MA, Cruz R, Bryson J, Escalettes F, Rosser SJ. 2020. Expanding and understanding
510   the CRISPR toolbox for *Bacillus subtilis* with MAD7 and dMAD7. Biotechnol Bioeng
511   117:1805-1816.

512   24.   Peters JE. 2019. Targeted transposition with Tn7 elements: safe sites, mobile plasmids,
513   CRISPR/Cas and beyond. Mol Microbiol 112:1635-1644.

514   25.   Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH. 2019. Transposon-encoded CRISPR-
515   Cas systems direct RNA-guided DNA integration. Nature 571:219-225.

516   26.   Strecker J, Ladha A, Gardner Z, Schmid-Burgk JL, Makarova KS, Koonin EV, Zhang F. 2019.
517   RNA-guided DNA insertion with CRISPR-associated transposases. Science 365:48-53.

518   27.   Thurtle-Schmidt DM, Lo TW. 2018. Molecular biology at the cutting edge: A review on
519   CRISPR/CAS9 gene editing for undergraduates. Biochem Mol Biol Educ 46:195-205.

520   28.   Ye B, Zhou C, Zhao L, Cheng S, Cheng D, Yan X. 2018. Unmarked genetic manipulation in
521   *Bacillus subtilis* by natural co-transformation. J Biotechnol 284:57-62.

29. Zhao H, Sachla AJ, Helmann JD. 2019. Mutations of the *Bacillus subtilis* YidC1 (SpoIIIJ)
insertase alleviate stress associated with σ^M-dependent membrane protein
overproduction. PLoS Genet 15:e1008263.
30. Patel Y, Zhao H, Helmann JD. 2020. A regulatory pathway that selectively up-regulates
elongasome function in the absence of class A PBPs. Elife 9.
31. Patel V, Wu Q, Chandrangsu P, Helmann JD. 2018. A metabolic checkpoint protein GlmR
is important for diverting carbon into peptidoglycan biosynthesis in *Bacillus subtilis*.
PLoS Genet 14:e1007689.
32. Patel V, Black KA, Rhee KY, Helmann JD. 2019. *Bacillus subtilis* PgcA moonlights as a
phosphoglucosamine mutase in support of peptidoglycan synthesis. PLoS Genet
15:e1008434.
33. Sun D, Wang L, Mao X, Fei M, Chen Y, Shen M, Qiu J. 2019. Chemical transformation
mediated CRISPR/Cas9 genome editing in Escherichia coli. Biotechnol Lett 41:293-303.
34. Trauth S, Bischofs IB. 2014. Ectopic integration vectors for generating fluorescent
promoter fusions in *Bacillus subtilis* with minimal dark noise. PLoS One 9:e98360.
537

538 **Table 1. Summary of efficiency results for *cis* and *trans* repair templates**

539

Base pairs of homology in repair template (left +right)	Total length of repair template	Plasmid	KanR colonies	MLSS clones	% MLSS	% efficiency for MLSS	Purpose
Cloned repair template							
1534 (750+784)	2410*	pAJS24	48	43	89%	100% (10/10)	*cpgA*::*erm*-->*rsgA* (Sau) heterologous complementation
2599 (1028+1571)	3893	pAJS25	197	131	66%	100% (10/10)	*yqgC*::*erm*-->*yqgC-sodA*-FLAG epitope fusion
2188 (725 +1463)	4281**	pAJS26	53	21	40%	100% (15/15)	*yqgC*::*erm*-->*yqgC-gfp* translation fusion
1405 (633+772)	2170	pAJS27	92	82	89%	100% (20/20)	*yceF*::*erm*-->*yceF**(Ile206Thr)
1719 bp (1028+691)	2202	pAJS28	56	46	82%	100% (46/46)	*yqgC*::*erm*-->deletion of intergenic *S936* element
546 (259+287)	696	pAJS29	855	186	22%	100% (25/25)	*yqgC*::*erm*-->Δ*yqgC* (markerless)
1594 (725+869)	1744	pAJS30	110	97	85%	100% (12/12)	*yqgC*::*erm*-->Δ*yqgC* (markerless)
Co-transformation with repair template‡							
1405 PCR (633+772)	2170	N/A	63	28	44%	18% (5/28)†	*yceF*::*erm*-->*yceF**(Ile206Thr)
yceF*(Ile206Thr) gDNA	N/A	N/A	96	26	27%	11% (3/28) †	*yceF*::*erm*-->*yceF**(Ile206Thr)
yceF*(Ile206Thr) gDNA	N/A	N/A	50	38	76%	13% (5/38)†	*yceF*::*erm*-->*yceF**(Ile206Thr)

540

541 N/A: not applicable

542 Column 1: Length of UP and DO homology is depicted in parenthesis.

543 *rsgA (*cpgA* homolog) of 876 bp was amplified from *S. aureus* Newman strain.

544 ** 715bp of GFP coding sequence was amplified from pGFP-star plasmid DNA.

545 † represents the fact that of 28 clones only 5 clones (for PCR-based) and 5 out of 38 clones (for

546 gDNA-based) showed PCR products.

547 ‡ co-transformation had different size transformants after 2 days on Kan+0.2% mannose

548 plates, and we found large colonies that appear rapidly usually did not show successful CRISPR

549 event.

550

Figure Legends

Figure 1. CRISPR-Cas9 Editing with an *erm* gRNA.

Plasmid pJOE8999 (7.8 kb; (11)) expresses Cas9 nuclease under a mannose-inducible

promoter and is temperature sensitive for replication in *B. subtilis.* Plasmid pAJS23

contains a cloned gRNA directed against the MLS resistance cassette (*erm* gene). This

erm-guide RNA (pink) can be used to target and cleave specific genome regions

containing integrated *erm* cassettes as present in the BKE collection of gene disruptants

(9). Repair templates can be provided in *trans* (left) by co-transformation of recipient

cells with pAJS23 and a repair template (either a PCR product of genomic DNA) or in

cis (right) by cloning of the repair template into pAJS23. Note that repair templates

should include DNA from the regions upstream (UP) and downstream (DO) of the

deleted gene in the targeted BKE strain. Engineered strains are cured of the

temperature-sensitive plasmid, and MLS^S (*erm*$^-$) colonies recovered for verification by

DNA sequencing.

Figure 2. Representative applications of CRISPR-Cas9 editing of BKE strains.

Recipient strains from the BKE collection (with specific genes replaced by an integrated

erm cassette) were transformed with a pAJS23 derivative carrying a cloned repair

template (see Table 1). **A.** The *cpgA::erm* recipeient was edited to replace the missing

cpgA gene with the ortholog from *S. aureus* (*Sau-cpgA* = *rsgA*) shown in pink. The *rsgA*

gene complements the cold-sensitivity of the *cpgA* mutant strain as shown by serial

dilution on LB plates incubated at 30 ˚C (inset). **B.** The *yqgC::erm* strain was used to

introduce a sequence encoding a FLAG tag (DYKDDDDK) at the C-terminus of SodA

and simultaneously re-introduce a functional *yqgC* gene. Western blot analysis of cells

harvested at the indicated cell density confirms the presence of the 23.5 kDa SodA-

FLAG protein (inset). **C.** The *yqgC::erm* strain was edited to express a C-terminal YqgC-

GFP (green fluorescent protein, org. *Aequorea victoria*) translational fusion. The

resultant strains were confirmed by DNA sequencing and the expression of GFP

confirmed by fluorescence microscopy of cells grown in LB to stationary phase (scale

bar = 10 microns). **D.** The *yceF::erm* strain was edited to express a mutant allele

(*yceF**) encoding the YceF Ile206Thr protein. This strain was generated using a cloned

repair template (pAJS27; Table 1) or by providing repair template DNA as a PCR

product or genomic DNA (Table 1). **E.** We used a *yqgC*::*erm* recipient strain (as shown

in panels B and C) to edit the operon by removing the intervening intergenic region,

including the RNA feature S936. The desired deletion was confirmed by visualization of

correctly sized (582 bp) PCR products (middle inset), which showed a reduction in size

relative to the 760 bp control product. **F.** A clean deletion of *yqgC*. The *yqgC*::*erm* locus

was replaced by a markerless deletion generated using plasmid pDR244 as described

(9).

593
594
595   **Figure 1**

596
597 **Figure 2**
598
599

600